1887

Journal of General Virology header logo

Volume 95, Issue 1

Comparative analysis of disease pathogenesis and molecular mechanisms of New World and Old World arenavirus infections Free

Abstract

Arenaviruses can cause fatal human haemorrhagic fever (HF) diseases for which vaccines and therapies are extremely limited. Both the New World (NW) and Old World (OW) groups of arenaviruses contain HF-causing pathogens. Although these two groups share many similarities, important differences with regard to pathogenicity and molecular mechanisms of virus infection exist. These closely related pathogens share many characteristics, including genome structure, viral assembly, natural host selection and the ability to interfere with innate immune signalling. However, members of the NW and OW viruses appear to use different receptors for cellular entry, as well as different mechanisms of virus internalization. General differences in disease signs and symptoms and pathological lesions in patients infected with either NW or OW arenaviruses are also noted and discussed herein. Whilst both the OW Lassa virus (LASV) and the NW Junin virus (JUNV) can cause disruption of the vascular endothelium, which is an important pathological feature of HF, the immune responses to these related pathogens seem to be quite distinct. Whereas LASV infection results in an overall generalized immune suppression, patients infected with JUNV seem to develop a cytokine storm. Additionally, the type of immune response required for recovery and clearance of the virus is different between NW and OW infections. These differences may be important to allow the viruses to evade host immune detection. Understanding these differences will aid the development of new vaccines and treatment strategies against deadly HF viral infections.

  • Received:
  • Accepted:
  • Published Online:
© Microbiology Society
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.057000-0
2014-01-01
2024-04-18
Loading full text...

Full text loading...

/deliver/fulltext/jgv/95/1/1.html?itemId=/content/journal/jgv/10.1099/vir.0.057000-0&mimeType=html&fmt=ahah

References

  1. Abraham J., Kwong J. A., Albariño C. G., Lu J. G., Radoshitzky S. R., Salazar-Bravo J., Farzan M., Spiropoulou C. F., Choe H. 2009; Host-species transferrin receptor 1 orthologs are cellular receptors for nonpathogenic new world clade B arenaviruses. PLoS Pathog 5:e1000358 [View Article][PubMed]
     [Google Scholar]
  2. Aguilar P. V., Camargo W., Vargas J., Guevara C., Roca Y., Felices V., Laguna-Torres V. A., Tesh R., Ksiazek T. G., Kochel T. J. 2009; Reemergence of Bolivian hemorrhagic fever, 2007–2008. Emerg Infect Dis 15:1526–1528 [View Article][PubMed]
     [Google Scholar]
  3. Albariño C. G., Bird B. H., Chakrabarti A. K., Dodd K. A., Flint M., Bergeron É., White D. M., Nichol S. T. 2011; The major determinant of attenuation in mice of the Candid1 vaccine for Argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain. J Virol 85:10404–10408 [View Article][PubMed]
     [Google Scholar]
  4. Alvarez C. P., Lasala F., Carrillo J., Muñiz O., Corbí A. L., Delgado R. 2002; C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans . J Virol 76:6841–6844 [View Article][PubMed]
     [Google Scholar]
  5. Ambrosio A., Saavedra M., Mariani M., Gamboa G., Maiza A. 2011; Argentine hemorrhagic fever vaccines. Hum Vaccin 7:694–700 [View Article][PubMed]
     [Google Scholar]
  6. Andersen K. G., Shylakhter I., Tabrizi S., Grossman S. R., Happi C. T., Sabeti P. C. 2012; Genome-wide scans provide evidence for positive selection of genes implicated in Lassa fever. Philos Trans R Soc Lond B Biol Sci 367:868–877 [View Article][PubMed]
     [Google Scholar]
  7. Andrews B. S., Theofilopoulos A. N., Peters C. J., Loskutoff D. J., Brandt W. E., Dixon F. J. 1978; Replication of dengue and Junin viruses in cultured rabbit and human endothelial cells. Infect Immun 20:776–781[PubMed]
     [Google Scholar]
  8. Andrews N. C., Fleming M. D., Levy J. E. 1999; Molecular insights into mechanisms of iron transport. Curr Opin Hematol 6:61–64 [View Article][PubMed]
     [Google Scholar]
  9. Baize S., Kaplon J., Faure C., Pannetier D., Georges-Courbot M.-C., Deubel V. 2004; Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J Immunol 172:2861–2869[PubMed] [CrossRef]
     [Google Scholar]
  10. Baize S., Marianneau P., Loth P., Reynard S., Journeaux A., Chevallier M., Tordo N., Deubel V., Contamin H. 2009; Early and strong immune responses are associated with control of viral replication and recovery in Lassa virus-infected cynomolgus monkeys. J Virol 83:5890–5903 [View Article][PubMed]
     [Google Scholar]
  11. Barrera Oro J. G., Eddy G. A. 1982; Characteristics of candidate live attenuated Junin virus vaccine. In IV International Conference on Comparative Virology Banff, Alberta, Canada: Abstract S4–10
    [Google Scholar]
  12. Barrera Oro J. G., Lupton H. W. 1988; Cross-protection against Machupo virus with Candid #1 live-attenuated Junin virus vaccine. I. The postvaccination prechallenge immune response. In Second International Conference on the Impact of Viral Diseases on the Development of Latin American Countries and the Caribbean Region Buenos Aires, Argentina:
     [Google Scholar]
  13. Beyer W. R., Pöpplau D., Garten W., von Laer D., Lenz O. 2003; Endoproteolytic processing of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P. J Virol 77:2866–2872 [View Article][PubMed]
     [Google Scholar]
  14. Bonthius D. J. 2012; Lymphocytic choriomeningitis virus: an underrecognized cause of neurologic disease in the fetus, child, and adult. Semin Pediatr Neurol 19:89–95 [View Article][PubMed]
     [Google Scholar]
  15. Borrow P., Oldstone M. B. A. 1994; Mechanism of lymphocytic choriomeningitis virus entry into cells. Virology 198:1–9 [View Article][PubMed]
     [Google Scholar]
  16. Botten J., Whitton J. L., Barrowman P., Sidney J., Whitmire J. K., Alexander J., Kotturi M. F., Sette A., Buchmeier M. J. 2010; A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans. J Virol 84:9947–9956 [View Article][PubMed]
     [Google Scholar]
  17. Bredenbeek P. J., Molenkamp R., Spaan W. J. M., Deubel V., Marianneau P., Salvato M. S., Moshkoff D., Zapata J., Tikhonov I. other authors 2006; A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 345:299–304 [View Article][PubMed]
     [Google Scholar]
  18. Brindley M. A., Hunt C. L., Kondratowicz A. S., Bowman J., Sinn P. L., McCray P. B. Jr, Quinn K., Weller M. L., Chiorini J. A., Maury W. 2011; Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein. Virology 415:83–94 [View Article][PubMed]
     [Google Scholar]
  19. Brunotte L., Lelke M., Hass M., Kleinsteuber K., Becker-Ziaja B., Günther S. 2011; Domain structure of Lassa virus L protein. J Virol 85:324–333 [View Article][PubMed]
     [Google Scholar]
  20. Buchmeier M., Bowen M., Peters C. 2001; Arenaviridae: The Viruses and Their Replication. In Fields Virology, 4th edn. pp. 1635–1668 Edited by Knipe D., Howley P. Philadelphia, PA: Lippincott-Raven Publisher;
     [Google Scholar]
  21. CDC (Centers for Disease Control and Prevention) 2008; Brief report: Lymphocytic choriomeningitis virus transmitted through solid organ transplantation – Massachusetts, 2008. MMWR Morb Mortal Wkly Rep 57:799–801[PubMed]
     [Google Scholar]
  22. Charrel R. N., de Lamballerie X. 2003; Arenaviruses other than Lassa virus. Antiviral Res 57:89–100 [View Article][PubMed]
     [Google Scholar]
  23. Childs J., Peters C. 1993; Ecology and epidemiology of arenaviruses and their hosts. In The Arenaviridae pp. 331–384 Edited by Salvato M. New York: Plenum Press; [View Article]
     [Google Scholar]
  24. Coimbra T. L. M., Nassar E. S., de Souza L. T. M., Ferreira I. B., Rocco I. M., Burattini M. N., Travassos da Rosa A. P. A., Vasconcelos P. F. C. other authors 1994; New arenavirus isolated in Brazil. Lancet 343:391–392 [View Article][PubMed]
     [Google Scholar]
  25. Cummins D., Fisher-Hoch S. P., Walshe K. J., Mackie I. J., McCormick J. B., Bennett D., Perez G., Farrar B., Machin S. J. 1989; A plasma inhibitor of platelet aggregation in patients with Lassa fever. Br J Haematol 72:543–548 [View Article][PubMed]
     [Google Scholar]
  26. Cummins D., McCormick J. B., Bennett D., Samba J. A., Farrar B., Machin S. J., Fisher-Hoch S. P. 1990a; Acute sensorineural deafness in Lassa fever. JAMA 264:2093–2096 [View Article][PubMed]
     [Google Scholar]
  27. Cummins D., Molinas F. C., Lerer G., Maiztegui J. I., Faint R., Machin S. J. 1990b; A plasma inhibitor of platelet aggregation in patients with Argentine hemorrhagic fever. Am J Trop Med Hyg 42:470–475[PubMed]
     [Google Scholar]
  28. de Bracco M. M. E., Rimoldi M. T., Cossio P. M., Rabinovich A., Maiztegui J. I., Carballal G., Arana R. M. 1978; Argentine hemorrhagic fever. Alterations of the complement system and anti-Junin-virus humoral response. N Engl J Med 299:216–221 [View Article][PubMed]
     [Google Scholar]
  29. de Manzione N., Salas R. A., Paredes H., Godoy O., Rojas L., Araoz F., Fulhorst C. F., Ksiazek T. G., Mills J. N. other authors 1998; Venezuelan hemorrhagic fever: clinical and epidemiological studies of 165 cases. Clin Infect Dis 26:308–313 [View Article][PubMed]
     [Google Scholar]
  30. Delgado S., Erickson B. R., Agudo R., Blair P. J., Vallejo E., Albariño C. G., Vargas J., Comer J. A., Rollin P. E. other authors 2008; Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog 4:e1000047 [View Article][PubMed]
     [Google Scholar]
  31. Demogines A., Abraham J., Choe H., Farzan M., Sawyer S. L. 2013; Dual host–virus arms races shape an essential housekeeping protein. PLoS Biol 11:e1001571 [View Article][PubMed]
     [Google Scholar]
  32. Eichler R., Lenz O., Strecker T., Eickmann M., Klenk H.-D., Garten W. 2003a; Identification of Lassa virus glycoprotein signal peptide as a trans-acting maturation factor. EMBO Rep 4:1084–1088 [View Article][PubMed]
     [Google Scholar]
  33. Eichler R., Lenz O., Strecker T., Garten W. 2003b; Signal peptide of Lassa virus glycoprotein GP-C exhibits an unusual length. FEBS Lett 538:203–206 [View Article][PubMed]
     [Google Scholar]
  34. Elsner B., Schwarz E., Mando O. G., Maiztegui J., Vilches A. 1973; Pathology of 12 fatal cases of Argentine hemorrhagic fever. Am J Trop Med Hyg 22:229–236[PubMed]
     [Google Scholar]
  35. Emonet S. F., Seregin A. V., Yun N. E., Poussard A. L., Walker A. G., de la Torre J. C., Paessler S. 2011; Rescue from cloned cDNAs and in vivo characterization of recombinant pathogenic Romero and live-attenuated Candid #1 strains of Junin virus, the causative agent of Argentine hemorrhagic fever disease. J Virol 85:1473–1483 [View Article][PubMed]
     [Google Scholar]
  36. Enria D. A., Maiztegui J. I. 1994; Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res 23:23–31 [View Article][PubMed]
     [Google Scholar]
  37. Enria D. A., Briggiler A. M., Levis S., Vallejos D., Maiztegui J. I., Canonico P. G. 1987; Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever. Antiviral Res 7:353–359 [View Article][PubMed]
     [Google Scholar]
  38. Enria D. A., Briggiler A. M., Sánchez Z. 2008; Treatment of Argentine hemorrhagic fever. Antiviral Res 78:132–139 [View Article][PubMed]
     [Google Scholar]
  39. Fan L., Briese T., Lipkin W. I. 2010; Z proteins of New World arenaviruses bind RIG-I and interfere with type I interferon induction. J Virol 84:1785–1791 [View Article][PubMed]
     [Google Scholar]
  40. Fischer S. A., Graham M. B., Kuehnert M. J., Kotton C. N., Srinivasan A., Marty F. M., Comer J. A., Guarner J., Paddock C. D. other authors 2006; Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 354:2235–2249 [View Article][PubMed]
     [Google Scholar]
  41. Fisher-Hoch S., McCormick J. B., Sasso D., Craven R. B. 1988; Hematologic dysfunction in Lassa fever. J Med Virol 26:127–135 [View Article][PubMed]
     [Google Scholar]
  42. Fisher-Hoch S. P., Hutwagner L., Brown B., McCormick J. B. 2000; Effective vaccine for lassa fever. J Virol 74:6777–6783 [View Article][PubMed]
     [Google Scholar]
  43. Flatz L., Rieger T., Merkler D., Bergthaler A., Regen T., Schedensack M., Bestmann L., Verschoor A., Kreutzfeldt M. other authors 2010; T cell-dependence of Lassa fever pathogenesis. PLoS Pathog 6:e1000836 [View Article][PubMed]
     [Google Scholar]
  44. Fulhorst C. E., Bowen M. D., Salas R. A., de Manzione N. M. C., Duno G., Utrera A., Ksiazek T. G., Peters C. J., Nichol S. T. other authors 1997; Isolation and characterization of pirital virus, a newly discovered South American arenavirus. Am J Trop Med Hyg 56:548–553[PubMed]
     [Google Scholar]
  45. Fulhorst C. F., Cajimat M. N. B., Milazzo M. L., Paredes H., de Manzione N. M. C., Salas R. A., Rollin P. E., Ksiazek T. G. 2008; Genetic diversity between and within the arenavirus species indigenous to western Venezuela. Virology 378:205–213 [View Article][PubMed]
     [Google Scholar]
  46. Geisbert T. W., Jones S., Fritz E. A., Shurtleff A. C., Geisbert J. B., Liebscher R., Grolla A., Ströher U., Fernando L. other authors 2005; Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2:e183 [View Article][PubMed]
     [Google Scholar]
  47. Gomez R. M., Pozner R. G., Lazzari M. A., D’Atri L. P., Negrotto S., Chudzinski-Tavassi A. M., Berría M. I., Schattner M. 2003; Endothelial cell function alteration after Junin virus infection. Thromb Haemost 90:326–333[PubMed]
     [Google Scholar]
  48. Goñi S. E., Iserte J. A., Ambrosio A. M., Romanowski V., Ghiringhelli P. D., Lozano M. E. 2006; Genomic features of attenuated Junín virus vaccine strain candidate. Virus Genes 32:37–41 [View Article][PubMed]
     [Google Scholar]
  49. Gramberg T., Hofmann H., Möller P., Lalor P. F., Marzi A., Geier M., Krumbiegel M., Winkler T., Kirchhoff F. other authors 2005; LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus. Virology 340:224–236 [View Article][PubMed]
     [Google Scholar]
  50. Groseth A., Hoenen T., Weber M., Wolff S., Herwig A., Kaufmann A., Becker S. 2011; Tacaribe virus but not Junin virus infection induces cytokine release from primary human monocytes and macrophages. PLoS Negl Trop Dis 5:e1137 [View Article][PubMed]
     [Google Scholar]
  51. Günther S., Lenz O. 2004; Lassa virus. Crit Rev Clin Lab Sci 41:339–390 [View Article][PubMed]
     [Google Scholar]
  52. Harmon B., Kozina C., Maar D., Carpenter T. S., Branda C. S., Negrete O. A., Carson B. D. 2013; Identification of critical amino acids within the nucleoprotein of Tacaribe virus important for anti-interferon activity. J Biol Chem 288:8702–8711 [View Article][PubMed]
     [Google Scholar]
  53. Harrison L. H., Halsey N. A., McKee K. T. Jr, Peters C. J., Barrera Oro J. G., Briggiler A. M., Feuillade M. R., Maiztegui J. I. 1999; Clinical case definitions for Argentine hemorrhagic fever. Clin Infect Dis 28:1091–1094 [View Article][PubMed]
     [Google Scholar]
  54. Hastie K. M., Kimberlin C. R., Zandonatti M. A., MacRae I. J., Saphire E. O. 2011; Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3′ to 5′ exonuclease activity essential for immune suppression. Proc Natl Acad Sci U S A 108:2396–2401 [View Article][PubMed]
     [Google Scholar]
  55. Heller M. V., Saavedra M. C., Falcoff R., Maiztegui J. I., Molinas F. C. 1992; Increased tumor necrosis factor-α levels in Argentine hemorrhagic fever. J Infect Dis 166:1203–1204 [View Article][PubMed]
     [Google Scholar]
  56. Heller M. V., Marta R. F., Sturk A., Maiztegui J. I., Hack C. E., Cate J. W., Molinas F. C. 1995; Early markers of blood coagulation and fibrinolysis activation in Argentine hemorrhagic fever. Thromb Haemost 73:368–373[PubMed]
     [Google Scholar]
  57. Jahrling P. B., Trotter R. W., Barrera Oro J. G., Lupton H. W., Cosgriff T. M., Lewis R. W., Parrish D. B., Smith S. B., Peters C. J. 1988; Cross-protection against Machupo virus with Candid #1 Junin virus vaccine: III, post-challenge clinical findings. In Second International Conference on the Impact of Viral Diseases on the Development of Latin American Countries and the Caribbean Region p. E3 Mar del Plata, Argentina:
     [Google Scholar]
  58. Jiang X., Dalebout T. J., Bredenbeek P. J., Carrion R. Jr, Brasky K., Patterson J., Goicochea M., Bryant J., Salvato M. S., Lukashevich I. S. 2011; Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine 29:1248–1257 [View Article][PubMed]
     [Google Scholar]
  59. Jiang X., Huang Q., Wang W., Dong H., Ly H., Liang Y., Dong C. 2013; Structures of arenaviral nucleoproteins with triphosphate dsRNA reveal a unique mechanism of immune suppression. J Biol Chem 288:16949–16959 [View Article][PubMed]
     [Google Scholar]
  60. Johnson K. M., Kuns M. L., Mackenzie R. B., Webb P. A., Yunker C. E. 1966; Isolation of Machupo virus from wild rodent Calomys callosus . Am J Trop Med Hyg 15:103–106[PubMed]
     [Google Scholar]
  61. Johnson K. M., Halstead S. B., Cohen S. N. 1967; Hemorrhagic fevers of Southeast Asia and South America: a comparative appraisal. Prog Med Virol 9:105–158[PubMed]
     [Google Scholar]
  62. Johnson K. M., McCormick J. B., Webb P. A., Smith E. S., Elliott L. H., King I. J. 1987; Clinical virology of Lassa fever in hospitalized patients. J Infect Dis 155:456–464 [View Article][PubMed]
     [Google Scholar]
  63. Kunz S., Sevilla N., McGavern D. B., Campbell K. P., Oldstone M. B. A. 2001; Molecular analysis of the interaction of LCMV with its cellular receptor α-dystroglycan. J Cell Biol 155:301–310 [View Article][PubMed]
     [Google Scholar]
  64. Kunz S., Rojek J. M., Kanagawa M., Spiropoulou C. F., Barresi R., Campbell K. P., Oldstone M. B. A. 2005; Posttranslational modification of α-dystroglycan, the cellular receptor for arenaviruses, by the glycosyltransferase LARGE is critical for virus binding. J Virol 79:14282–14296 [View Article][PubMed]
     [Google Scholar]
  65. Levis S. C., Saavedra M. C., Ceccoli C., Feuillade M. R., Enria D. A., Maiztegui J. I., Falcoff R. 1985; Correlation between endogenous interferon and the clinical evolution of patients with Argentine hemorrhagic fever. J Interferon Res 5:383–389 [View Article][PubMed]
     [Google Scholar]
  66. Lukashevich I. S. 2013; The search for animal models for Lassa fever vaccine development. Expert Rev Vaccines 12:71–86 [View Article][PubMed]
     [Google Scholar]
  67. Lukashevich I. S., Clegg J. C. S., Sidibe K. 1993; Lassa virus activity in Guinea: distribution of human antiviral antibody defined using enzyme-linked immunosorbent assay with recombinant antigen. J Med Virol 40:210–217 [View Article][PubMed]
     [Google Scholar]
  68. Lukashevich I. S., Maryankova R., Vladyko A. S., Nashkevich N., Koleda S., Djavani M., Horejsh D., Voitenok N. N., Salvato M. S. 1999; Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-α gene expression. J Med Virol 59:552–560 [View Article][PubMed]
     [Google Scholar]
  69. Lukashevich I. S., Carrion R. Jr, Salvato M. S., Mansfield K., Brasky K., Zapata J., Cairo C., Goicochea M., Hoosien G. E. other authors 2008; Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 26:5246–5254 [View Article][PubMed]
     [Google Scholar]
  70. MacNeil A., Ströher U., Farnon E., Campbell S., Cannon D., Paddock C. D., Drew C. P., Kuehnert M., Knust B. other authors 2012; Solid organ transplant-associated lymphocytic choriomeningitis, United States, 2011. Emerg Infect Dis 18:1256–1262 [View Article][PubMed]
     [Google Scholar]
  71. Mahanty S., Bausch D. G., Thomas R. L., Goba A., Bah A., Peters C. J., Rollin P. E. 2001; Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever. J Infect Dis 183:1713–1721 [View Article][PubMed]
     [Google Scholar]
  72. Mahanty S., Hutchinson K., Agarwal S., McRae M., Rollin P. E., Pulendran B. 2003; Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 170:2797–2801[PubMed] [CrossRef]
     [Google Scholar]
  73. Maiztegui J. I., Laguens R. P., Cossio P. M., Casanova M. B., de la Vega M. T., Ritacco V., Segal A., Fernández N. J., Arana R. M. 1975; Ultrastructural and immunohistochemical studies in five cases of Argentine hemorrhagic fever. J Infect Dis 132:35–43 [View Article][PubMed]
     [Google Scholar]
  74. Maiztegui J. I., Fernandez N. J., de Damilano A. J. 1979; Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 314:1216–1217 [View Article][PubMed]
     [Google Scholar]
  75. Marsh E. W., Leopold P. L., Jones N. L., Maxfield F. R. 1995; Oligomerized transferrin receptors are selectively retained by a lumenal sorting signal in a long-lived endocytic recycling compartment. J Cell Biol 129:1509–1522 [View Article][PubMed]
     [Google Scholar]
  76. Marta R. F., Montero V. S., Hack C. E., Sturk A., Maiztegui J. I., Molinas F. C. 1999; Proinflammatory cytokines and elastase-α-1-antitrypsin in Argentine hemorrhagic fever. Am J Trop Med Hyg 60:85–89[PubMed]
     [Google Scholar]
  77. Martinez M. G., Cordo S. M., Candurra N. A. 2007; Characterization of Junin arenavirus cell entry. J Gen Virol 88:1776–1784 [View Article][PubMed]
     [Google Scholar]
  78. Martinez M. G., Forlenza M. B., Candurra N. A. 2009; Involvement of cellular proteins in Junin arenavirus entry. Biotechnol J 4:866–870 [View Article][PubMed]
     [Google Scholar]
  79. Martínez-Sobrido L., Giannakas P., Cubitt B., García-Sastre A., de la Torre J. C. 2007; Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J Virol 81:12696–12703 [View Article][PubMed]
     [Google Scholar]
  80. McCormick J. B. 1999; Lassa fever. In Emergence and Control of Rodent-borne Viral Diseases pp. 177–195 Edited by Saluzzo J. F., Dodet B. Amsterdam: Elsevier;
     [Google Scholar]
  81. McCormick J. B., Fisher-Hoch S. P. 2002; Lassa fever. Curr Top Microbiol Immunol 262:75–109 [View Article][PubMed]
     [Google Scholar]
  82. McCormick J. B., Webb P. A., Krebs J. W., Johnson K. M., Smith E. S. 1987a; A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis 155:437–444 [View Article][PubMed]
     [Google Scholar]
  83. McCormick J. B., King I. J., Webb P. A., Johnson K. M., O’Sullivan R., Smith E. S., Trippel S., Tong T. C. 1987b; A case–control study of the clinical diagnosis and course of Lassa fever. J Infect Dis 155:445–455 [View Article][PubMed]
     [Google Scholar]
  84. McCormick J. B., Mitchell S. W., Kiley M. P., Ruo S., Fisher-Hoch S. P. 1992; Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys. J Med Virol 37:1–7 [View Article][PubMed]
     [Google Scholar]
  85. Mills J. N., Ellis B. A., McKee K. T. Jr, Ksiazek T. G., Oro J. G., Maiztegui J. I., Calderon G. E., Peters C. J., Childs J. E. 1991; Junin virus activity in rodents from endemic and nonendemic loci in central Argentina. Am J Trop Med Hyg 44:589–597[PubMed]
     [Google Scholar]
  86. Molinas F. C., de Bracco M. M. E., Maiztegui J. I. 1989; Hemostasis and the complement system in Argentine hemorrhagic fever. Rev Infect Dis 11:Suppl. 4S762–S770 [View Article][PubMed]
     [Google Scholar]
  87. Monath T. P., Casals J. 1975; Diagnosis of Lassa fever and the isolation and management of patients. Bull World Health Organ 52:707–715[PubMed]
     [Google Scholar]
  88. Montardit A. I., Fernandez M. J., DeSensi M. R. F., Damilano A. J., Maiztegui J. I. 1979; Neutralizacion de la viremia en enfermos de fiebre hemorragica Argentina tratados con plasma inmune. Medicina (B Aires) 39:799
     [Google Scholar]
  89. Moraz M.-L., Kunz S. 2011; Pathogenesis of arenavirus hemorrhagic fevers. Expert Rev Anti Infect Ther 9:49–59 [View Article][PubMed]
     [Google Scholar]
  90. Moraz M.-L., Pythoud C., Turk R., Rothenberger S., Pasquato A., Campbell K. P., Kunz S. 2013; Cell entry of Lassa virus induces tyrosine phosphorylation of dystroglycan. Cell Microbiol 15:689–700 [View Article][PubMed]
     [Google Scholar]
  91. Morin B., Coutard B., Lelke M., Ferron F., Kerber R., Jamal S., Frangeul A., Baronti C., Charrel R. other authors 2010; The N-terminal domain of the arenavirus L protein is an RNA endonuclease essential in mRNA transcription. PLoS Pathog 6:e1001038 [View Article][PubMed]
     [Google Scholar]
  92. Oldstone M. B. A., Campbell K. P. 2011; Decoding arenavirus pathogenesis: essential roles for alpha-dystroglycan-virus interactions and the immune response. Virology 411:170–179 [View Article][PubMed]
     [Google Scholar]
  93. Paessler S., Walker D. H. 2013; Pathogenesis of the viral hemorrhagic fevers. Annu Rev Pathol 8:411–440 [View Article][PubMed]
     [Google Scholar]
  94. Pannetier D., Faure C., Georges-Courbot M.-C., Deubel V., Baize S. 2004; Human macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in response to Mopeia virus infection. J Virol 78:10516–10524 [View Article][PubMed]
     [Google Scholar]
  95. Pannetier D., Reynard S., Russier M., Journeaux A., Tordo N., Deubel V., Baize S. 2011; Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus. J Virol 85:8293–8306 [View Article][PubMed]
     [Google Scholar]
  96. Pasqual G., Rojek J. M., Masin M., Chatton J.-Y., Kunz S. 2011; Old world arenaviruses enter the host cell via the multivesicular body and depend on the endosomal sorting complex required for transport. PLoS Pathog 7:e1002232 [View Article][PubMed]
     [Google Scholar]
  97. Paweska J. T., Sewlall N. H., Ksiazek T. G., Blumberg L. H., Hale M. J., Lipkin W. I., Weyer J., Nichol S. T., Rollin P. E. other authors 2009; Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerg Infect Dis 15:1598–1602 [View Article][PubMed]
     [Google Scholar]
  98. Perez M., de la Torre J. C. 2003; Characterization of the genomic promoter of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol 77:1184–1194 [View Article][PubMed]
     [Google Scholar]
  99. Peters C. J. 2006; Lymphocytic choriomeningitis virus – an old enemy up to new tricks. N Engl J Med 354:2208–2211 [View Article][PubMed]
     [Google Scholar]
  100. Pfau C. J. 1996; Arenaviruses. In Medical Microbiology, 4th edn. Edited by Baron S. Galveston, TX: University of Texas Medical Branch at Galveston;
     [Google Scholar]
  101. Pinschewer D. D., Perez M., de la Torre J. C. 2005; Dual role of the lymphocytic choriomeningitis virus intergenic region in transcription termination and virus propagation. J Virol 79:4519–4526 [View Article][PubMed]
     [Google Scholar]
  102. Pythoud C., Rodrigo W. W. S. I., Pasqual G., Rothenberger S., Martínez-Sobrido L., de la Torre J. C., Kunz S. 2012; Arenavirus nucleoprotein targets interferon regulatory factor-activating kinase IKKϵ. J Virol 86:7728–7738 [View Article][PubMed]
     [Google Scholar]
  103. Qi X., Lan S., Wang W., Schelde L. M., Dong H., Wallat G. D., Ly H., Liang Y., Dong C. 2010; Cap binding and immune evasion revealed by Lassa nucleoprotein structure. Nature 468:779–783 [View Article][PubMed]
     [Google Scholar]
  104. Quirin K., Eschli B., Scheu I., Poort L., Kartenbeck J., Helenius A. 2008; Lymphocytic choriomeningitis virus uses a novel endocytic pathway for infectious entry via late endosomes. Virology 378:21–33 [View Article][PubMed]
     [Google Scholar]
  105. Radoshitzky S. R., Abraham J., Spiropoulou C. F., Kuhn J. H., Nguyen D., Li W., Nagel J., Schmidt P. J., Nunberg J. H. other authors 2007; Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature 446:92–96 [View Article][PubMed]
     [Google Scholar]
  106. Raju R., Raju L., Hacker D., Garcin D., Compans R., Kolakofsky D. 1990; Nontemplated bases at the 5′ ends of Tacaribe virus mRNAs. Virology 174:53–59 [View Article][PubMed]
     [Google Scholar]
  107. Rodrigo W. W. S. I., Ortiz-Riaño E., Pythoud C., Kunz S., de la Torre J. C., Martínez-Sobrido L. 2012; Arenavirus nucleoproteins prevent activation of nuclear factor kappa B. J Virol 86:8185–8197 [View Article][PubMed]
     [Google Scholar]
  108. Rojek J. M., Kunz S. 2008; Cell entry by human pathogenic arenaviruses. Cell Microbiol 10:828–835 [View Article][PubMed]
     [Google Scholar]
  109. Rojek J. M., Campbell K. P., Oldstone M. B. A., Kunz S. 2007a; Old World arenavirus infection interferes with the expression of functional α-dystroglycan in the host cell. Mol Biol Cell 18:4493–4507 [View Article][PubMed]
     [Google Scholar]
  110. Rojek J. M., Spiropoulou C. F., Campbell K. P., Kunz S. 2007b; Old World and clade C New World arenaviruses mimic the molecular mechanism of receptor recognition used by α-dystroglycan’s host-derived ligands. J Virol 81:5685–5695 [View Article][PubMed]
     [Google Scholar]
  111. Rojek J. M., Perez M., Kunz S. 2008a; Cellular entry of lymphocytic choriomeningitis virus. J Virol 82:1505–1517 [View Article][PubMed]
     [Google Scholar]
  112. Rojek J. M., Sanchez A. B., Nguyen N. T., de la Torre J.-C., Kunz S. 2008b; Different mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses. J Virol 82:7677–7687 [View Article][PubMed]
     [Google Scholar]
  113. Rojek J. M., Moraz M.-L., Pythoud C., Rothenberger S., Van der Goot F. G., Campbell K. P., Kunz S. 2012; Binding of Lassa virus perturbs extracellular matrix-induced signal transduction via dystroglycan. Cell Microbiol 14:1122–1134 [View Article][PubMed]
     [Google Scholar]
  114. Sabeti P. C., Varilly P., Fry B., Lohmueller J., Hostetter E., Cotsapas C., Xie X., Byrne E. H., McCarroll S. A. other authors 2007; Genome-wide detection and characterization of positive selection in human populations. Nature 449:913–918 [View Article][PubMed]
     [Google Scholar]
  115. Sevilla N., Kunz S., Holz A., Lewicki H., Homann D., Yamada H., Campbell K. P., de La Torre J. C., Oldstone M. B. A. 2000; Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J Exp Med 192:1249–1260 [View Article][PubMed]
     [Google Scholar]
  116. Shimojima M., Ströher U., Ebihara H., Feldmann H., Kawaoka Y. 2012; Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry. J Virol 86:2067–2078 [View Article][PubMed]
     [Google Scholar]
  117. Spiropoulou C. F., Kunz S., Rollin P. E., Campbell K. P., Oldstone M. B. A. 2002; New World arenavirus clade C, but not clade A and B viruses, utilizes α-dystroglycan as its major receptor. J Virol 76:5140–5146 [View Article][PubMed]
     [Google Scholar]
  118. Stinebaugh B. J., Schloeder F. X., Johnson K. M., Mackenzie R. B., Entwisle G., De Alba E. 1966; Bolivian hemorrhagic fever. A report of four cases. Am J Med 40:217–230 [View Article][PubMed]
     [Google Scholar]
  119. Tesh R. B., Jahrling P. B., Salas R., Shope R. E. 1994; Description of Guanarito virus (Arenaviridae: Arenavirus), the etiologic agent of Venezuelan hemorrhagic fever. Am J Trop Med Hyg 50:452–459[PubMed]
     [Google Scholar]
  120. Vela E. 2012; Animal models, prophylaxis, and therapeutics for arenavirus infections. Viruses 4:1802–1829 [View Article][PubMed]
     [Google Scholar]
  121. Vela E. M., Zhang L., Colpitts T. M., Davey R. A., Aronson J. F. 2007; Arenavirus entry occurs through a cholesterol-dependent, non-caveolar, clathrin-mediated endocytic mechanism. Virology 369:1–11 [View Article][PubMed]
     [Google Scholar]
  122. Vieth S., Torda A. E., Asper M., Schmitz H., Günther S. 2004; Sequence analysis of L RNA of Lassa virus. Virology 318:153–168 [View Article][PubMed]
     [Google Scholar]
  123. Walker D. H., McCormick J. B., Johnson K. M., Webb P. A., Komba-Kono G., Elliott L. H., Gardner J. J. 1982a; Pathologic and virologic study of fatal Lassa fever in man. Am J Pathol 107:349–356[PubMed]
     [Google Scholar]
  124. Walker D. H., McCormick J. B., Johnson K. M., Webb P. A., Komba-Kono G., Elliott L. H., Gardner J. J. 1982b; Pathologic and virologic study of fatal Lassa fever in man. Am J Pathol 107:349–356[PubMed]
     [Google Scholar]
  125. Webb P. A., Justines G., Johnson K. M. 1975; Infection of wild and laboratory animals with Machupo and Latino viruses. Bull World Health Organ 52:493–499[PubMed]
     [Google Scholar]
  126. Weissenbacher M. C., Laguens R. P., Coto C. E. 1987; Argentine hemorrhagic fever. Curr Top Microbiol Immunol 134:79–116 [View Article][PubMed]
     [Google Scholar]
  127. Yamamoto T., Kato Y., Karita M., Kawaguchi M., Shibata N., Kobayashi M. 2004; Expression of genes related to muscular dystrophy with lissencephaly. Pediatr Neurol 31:183–190 [View Article][PubMed]
     [Google Scholar]
  128. York J., Nunberg J. H. 2007; Distinct requirements for signal peptidase processing and function in the stable signal peptide subunit of the Junín virus envelope glycoprotein. Virology 359:72–81 [View Article][PubMed]
     [Google Scholar]
  129. York J., Romanowski V., Lu M., Nunberg J. H. 2004; The signal peptide of the Junín arenavirus envelope glycoprotein is myristoylated and forms an essential subunit of the mature G1-G2 complex. J Virol 78:10783–10792 [View Article][PubMed]
     [Google Scholar]
  130. Zapata J. C., Salvato M. S. 2013; Arenavirus variations due to host-specific adaptation. Viruses 5:241–278 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.057000-0
Loading
Comparative analysis of disease pathogenesis and molecular mechanisms of New World and Old World arenavirus infections
J. Gen. Virol. 95, 1 (2014); https://doi.org/10.1099/vir.0.057000-0
/content/journal/jgv/10.1099/vir.0.057000-0
/content/journal/jgv/10.1099/vir.0.057000-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error